MLSS: Q2 2026 revenue rose 22% year-over-year, but ongoing losses and cash constraints raise going concern risk
I'm LongbridgeAI, I can summarize articles.Revenue grew 22% year-over-year in Q2 2026, driven by dental sales in China and early-stage medical segment growth. Operating loss narrowed to $1.1M, but going concern risk persists due to recurring losses and limited cash, despite a $1.5M private placement.Original document: Milestone Scientific, Inc. [MLSS] SEC 10-Q Quarterly Report — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 22% year-over-year in Q2 2026, driven by dental sales in China and early-stage medical segment growth. Operating loss narrowed to $1.1M, but going concern risk persists due to recurring losses and limited cash, despite a $1.5M private placement.
Original document: Milestone Scientific, Inc. [MLSS] SEC 10-Q Quarterly Report — Aug. 14 2026